To review the published data related to the rise and fall of three different therapeutic approaches, which were investigated to lower cardiovascular disease (CVD) risk.
INTRODUCTION
Cardiovascular disease (CVD) remains a major burden for morbidity and mortality in our societies, despite a wide array of currently available interventions to lower CVD risk. The notion that the majority of patients continue to suffer from CVD events has resulted in a tendency to advocate more aggressive use of current therapies in national guidelines. The fact that the target level for LDL cholesterol (LDL-C) is continuously decreasing over time in more recent guidelines is an example thereof [1] .
In addition, residual CVD risk has prompted a quest for additional therapies. In recent years, a number of novel targets for therapy have been identified and the rationale to target a specific pathway was largely based on data derived from epidemiological or preclinical studies. A number of new approaches reached phase II and phase III of drug development, but safety or lack of efficacy has resulted in premature termination of a number of clinical studies and further development of these therapies.
In the current review, we will discuss three of these novel targets for therapy, which failed to show adequate safety and efficacy in late clinical development.
THYROMIMETICS
Thyroid hormones are produced by the thyroid gland in an endocrinological feedback loop involving stimulation by the anterior pituitary and the hypothalamus. They play an important role in the overall regulation of metabolic rate.
Thyroid hormone and lipids
Patients with hypothyroidism are characterized, among others, by the presence of hypercholesterolemia, and conversely, low lipid levels are commonly seen in patients with hyperthyroidism. The prevalence of hypothyroidism in patients referred to a Lipid Clinic is approximately two times that in the general population [2] .
These clinical observations prompted studies examining the effects of thyroxin, a thyroid hormone analogue, on plasma cholesterol levels. Thyroxin resulted in reduced plasma cholesterol, but cardiac and other side-effects limited its potential to be applied in the prevention setting [3, 4] .
Thyroid hormones affect biological processes upon interaction with nuclear receptors and subsequent binding to thyroid receptor responsive elements (TREs) within the promotor regions of various target genes. Based on the expanding knowledge on how thyroid hormones impact nuclear receptors, novel therapies have been developed that more specifically target its lipid-modulating actions.
Two thyroid receptors (TRa and TRb) have been identified, and studies in mice models [5] have increased our understanding about impact on lipid metabolism of these receptors. TRa is mostly expressed in muscle and brown adipose tissue, whereas TRb is mainly expressed in hepatic cells and is involved in cholesterol and bile acid metabolism [6] .
TRb affects plasma cholesterol through a number of pathways. First, activation of TRb increases LDL-receptor (LDL-R) expression [7] . Second, thyroxin promotes 7a-hydroxylase-mediated cholesterol and bile secretion, resulting in a decreased hepatic cholesterol pool. This induces SREBP-2-mediated LDL-R upregulation [8] . Third, TRb stimulation affects reverse cholesterol transport, via upregulation of scavenger receptor B1 (SR-B1) [9 & ], a hepatic transporter of cholesteryl esters derived from HDL cholesterol (HDL-C) [10] . Moreover, apolipoprotein A1 (apoA1) synthesis has been shown to be increased in mice treated with a TRb agonist [9 & ,11] . It is commonly appreciated that the thyroxinmediated changes in cholesterol levels are primarily caused by stimulation of TRb in the liver and cardiac side-effects of thyroxin are mediated by TRa. As a consequence, selective TRb agonists were considered a promising lipid-lowering approach without causing some of thyroxin's side-effects [11] .
Although several selective thyroid hormone analogues were shown to be effective in animal studies in the 1980s, it was not until recent that the first human studies were undertaken with these compounds [12] .
Thyroid hormone receptor agonists in clinical trials
Eprotirome (formerly known as KB2115, KaroBio, Huddinge, Sweden), a selective TRb agonist, has been tested in over 300 participants in randomized clinical trials (RCTs). The safety and efficacy of eprotirome monotherapy was evaluated in a phase I study in 24 moderately overweight and hypercholesterolemic patients, while using a single (50-2000 mg) and multiple ascending dosing (50, 100, and 200 mg) regimen [13 & ]. No symptoms or laboratory signs of musculoskeletal side-effects were noted and no drug-related effects on the cardiovascular system were detected during the 2-week study (i.e., heart rate, blood pressure). However, mild increases in transaminase levels were noted, and alanine aminotransferase (ALT) levels reached three times upper limit of normal in one patient. In the multiple ascending dose study, LDL-C levels decreased by 40% at the two highest doses of eprotirome (100 and 200 mg daily). Eprotirome did not affect whole body cholesterol synthesis, HDL-C, and Lp(a) levels.
These promising results led to the initiation of a larger phase IIb RCT designed to investigate the effect of eprotirome in statin-treated patients with
KEY POINTS
Markers for CVD outcomes in animal and epidemiological studies do not necessarily imply that therapeutic interventions that specifically alter these markers will result in the anticipated beneficial clinical outcome.
Thyromimetics, sPLA 2 inhibitors, and acyl coenzyme A: cholesterol acyltransferase (ACAT) inhibitors were considered agents to lower CVD risk. Clinical trials addressing the effects of these agents did, however, not show beneficial effects.
LDL-C levels above 3 mmol/l [14 && ]. In total, 184 patients were randomly allocated to 12 weeks of treatment with eprotirome (25, 50, or 100 mg/day) or placebo, while all patients continued statin use at the dosages administered prior to the study. At the end of the treatment period, mean reductions in serum LDL-C were 22, 28, and 32% in patients treated with eprotirome 25, 50, and 100 mg/day respectively, compared with a 7% decrease in patients who received placebo (P <0.001).
Similar reductions were seen for apolipoprotein B (apoB), Lp(a), and triglyceride levels. HDL-C and apoA1 levels decreased slightly. A summary of the effects of eprotirome on lipids and lipoproteins is given in Table 1 .
ALT levels increased to more than three times upper limit of normal in two patients (receiving 25 and 50 mg), which was ascribed to alcohol abuse in one. Eprotirome treatment was not associated with effects on bone and the heart. Importantly, endogenous thyroid hormone levels remained within the reference range, indicating that interference with the hypothalamic-pituitary-thyroid axis was limited.
Eprotirome was subsequently tested in a phase III trial. This trial intended to include 630 patients with heterozygous familial hypercholesterolemia, and was designed with a follow-up of 2 years. However, only 4 months after the first patient was randomized, results of a study indicated a dosedependent deleterious effect on cartilage tissue in dogs long term treated with eprotirome. The phase III trial was prematurely discontinued in light of this potential hazardous effect in patients who were deemed to have to be treated for a long period of time (http://www.karobio.com/investormedia/ pressreleaser/pressrelease?pid¼639535).
This side-effect is incompletely understood. Thyroid hormone has been shown to impact cartilage matrix synthesis and mineralization through its interaction with TRa and TRb, and this is in line with the clinical observation of growth retardation in children with hypothyroidism and in patients with thyroid hormone receptor mutations [15] .
In addition, recent genome-wide association studies have indicated that common variants in the DIO2 and DIO3 (coding for enzymes converting T3 into T4) loci are associated with increased risk of osteoarthritis [16] . Moreover, thyroid hormone has been shown to directly influence cartilage in rats with chemically induced hypothyroidism [17] . Although eprotirome appears to exert little direct effect outside the liver, the thyroid hormone-like effects may have mimicked the effects of an increased expression of DIO2, stimulating chondrocyte maturation.
Future perspectives
The development of other thyromimetics has been halted and this is likely to be related to the negative results in the eprotirome-treated animals.
The clinical trial that aimed to address the effects of MB-07811 (a thyromimetic produced by Metabasis Inc., recently acquired by Ligand Pharmaceuticals, La Jolla, California, USA) in patients with heterozygous FH was withdrawn (http://clinicaltrials.gov/ct2/ results?term¼mb07811&Search¼Search. Internet communication).
Moreover, to the best of our knowledge, there are no ongoing or planned trials investigating the effects of GC-1 (formerly known as QRX431, QuatRx; Ann Arbor, Michigan, USA).
SECRETORY PHOSPHOLIPASE A2 INHIBITORS
Secretory phospholipases A 2 (sPLA 2 ) comprise a family of enzymes that belong to the superfamily of phospholipase A 2 enzymes, which hydrolyze phospholipids at the sn-2 bond, forming lysophospholipids and free fatty acids. These are subsequently converted into second messengers, such as eicosanoids and platelet-activating factor, with important roles in inflammation, immunity, and atherosclerosis [18] . At least 12 sPLA 2 isoforms have been identified, six of which have been found in atherosclerotic lesions [19] . LDL cholesterol À7 À22 À28 À32
ApoB À6 À20 À24 À30
Lp(a) À10 À27 À32 À43
The levels of circulating sPLA 2 have been found to be higher in CVD patients compared with controls, and elevated circulating sPLA 2 is associated with increased risk of future coronary events [20] .
Secretory phospholipase A2 and lipids
An increasing amount of evidence accentuates the contributing role of inflammation in atherogenesis and plaque instability [21] . In line with this is the finding that systemic inflammatory markers are strong predictors of subsequent cardiovascular events [22] . As a consequence, immune-modulating pharmacological strategies have gained interest in order to mitigate the process of atherosclerosis [21] .
Increased plaque formation was found in mice overexpressing sPLA 2 enzymes while fed a high fat/high cholesterol diet [23] [24] [25] [26] . sPLA 2 has been shown to directly affect the composition of lipids and lipoproteins. In combination with the observed decreases in levels of HDL-C, this leaves the LDL particles prone to oxidation, thereby forming oxidized, small dense LDL particles, with important proatherogenic propensity [19, 23, 27, 28] .
A summary of the proatherogenic consequences of elevated sPLA 2 levels is given in Table 2 .
Although inhibition of sPLA 2 has been shown ineffective in treating inflammatory diseases such as rheumatoid arthritis [29] , the association between sPLA 2 activity and CVD risk raised interest in sPLA 2 inhibition as a target for CVD prevention. Indeed, treatment with inhibitors of sPLA 2 caused a favorable shift in lipid profiles and a highly significant reduction in atherosclerotic plaque formation in apoE-null mice [30] . In particular, sPLA 2 -IIa and Lp-PLA 2 have gained prominence in cardiovascular research.
Secretory phospholipase A2 antagonists in clinical trials
Varespladib, a sPLA 2 inhibitor with specificity toward the sPLA 2 -IIA, sPLA 2 -V, and sPLA 2 -X isoforms has been tested in several trials. A total of 393 individuals with stable CVD were randomized in a phase II trial (PLASMA; Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease, NCT00455546) to either placebo or four different doses of varespladib, varying from 50 to 500 mg, twice daily. The main endpoints were sPLA 2 concentration and activity, which have been shown to be strong predictors of subsequent heart disease. Patients were treated for 8 weeks, after which a highly significant dose-dependent decrease in sPLA 2 -IIA concentration of 86.7% was found. A 9.8% additional decrease in LDL-C was found in patients on statins, and this decrease was mainly attributable to a reduction of small dense LDL. No serious adverse events were recorded [31 && ].
The promising results of varespladib in the PLASMA trial prompted the initiation of a phase II trial (PLASMA II). The PLASMA II trial was designed to investigate the efficacy of varespladib when used once daily in patients with stable coronary heart disease (CHD) concomitantly treated with statins. A total of 135 patients were randomized to either 250 or 500 mg varespladib once daily or placebo for 8 weeks.
Compared with the placebo group, varespladibtreated patients showed a dose-dependent reduction in sPLA 2 -IIA. Unlike the results derived in the PLASMAi trial, varespladib did not lower levels of small dense LDL.
In line with the results of the PLASMA-I trial, the PLASMA-II trial indicated that varespladib effectively decreases plasma levels of sPLA 2 IIA and causes a favorable shift in biomarkers of subsequent heart disease (i.e., LDL-C and non-HDL-C) [32] .
Whereas the PLASMA trials addressed the effect of varespladib in patients with stable CHD, the FRANCIS (Fewer Recurrent Acute coronary events with Near-Term Cardiovascular Inflammation Suppression) trial was designed for patients with an acute coronary syndrome (ACS). A total of [33] .
The SPIDER-PCI [(sPLA 2 Inhibition to Decrease Enzyme Release After PCI Trial (NCT00533039)] trial investigated whether varespladib could effectively decrease myocardial necrosis after elective percutaneous coronary intervention (PCI). A total of 144 patients were randomized to either 500 mg of varespladib or placebo, from 3 to 5 days prior to PCI until 5 days after PCI. Primary endpoints were markers of myocardial necrosis: troponin-I and creatine kinase-MB (CK-MB). Varespladib was shown not to decrease myocardial necrosis after elective PCI, despite all previous positive biomarker results [34] .
The phase III VISTA-16 trial (Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes NCT01130246) was designed to investigate the safety and efficacy of varespladib treatment on morbidity and mortality when added to atorvastatin and standard of care in ACS patients. A total of 5189 patients were randomized to 500 mg of varespladib daily or placebo for 16 weeks. The first patient was enrolled in June 2010. In March, 2012, the data safety monitoring board of the VISTA-16 trial recommended termination of the trial due to lack of efficacy (http://www.anthera.com/studies_vista-16.htm. Internet communication). The peerreviewed reports about the results of the VISTA-16 are eagerly awaited. The company website states that 'At the time of study termination the hazard ratio for the primary endpoint was 1.244 (P ¼ 0.155). The hazard ratio for the combination of cardiovascular death, nonfatal myocardial infarction, and stroke was statistically significant: hazard ratio 1.436 P ¼ 0.025. This is primarily driven by the increased occurrence of nonfatal myocardial infarction: hazard ratio 1.686 P ¼ 0.009.'
Future perspectives
The counterintuitive and disappointing results of the VISTA-16 trial obviously have resulted in serious questioning whether members of the phospholipase family per se should be targeted to reduce CVD risk.
The clinical effects of the only other inhibitor targeting a phospholipase, darapladib (targeting Lp-PLA 2 ), are largely unknown and the SOLID-TIMI 52 (Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction NCT01000727) is designed to address this question [35] .
ACYL COENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS
ACAT intracellularly esterifies cholesterol, forming hydrophobic cholesteryl esters. ACAT-1 is expressed in most cell types, including macrophages and smooth muscle cells, whereas ACAT-2 is primarily found in small intestinal and hepatic cells [36] .
Whereas inhibition of ACAT-1 should decrease foam cell formation by preventing esterification of cholesterol in macrophages, inhibition of ACAT-2 should prevent intestinal cholesterol absorption by decreasing chylomicron formation.
Acyl coenzyme A:cholesterol acyltransferase inhibition and lipids
Initial experiments in which animals were treated with nonspecific inhibitors of ACAT yielded compelling results indicating that ACAT inhibition effectively prevents the deposition of cholesterol in the vascular wall [37] [38] [39] . ACAT-1-knockout mice, however, developed severe cutaneous xanthomatosis, and depositions of unesterified cholesterol in the brain. Moreover, effects on atherogenesis were inconsistent [40] [41] [42] [43] . This discrepancy was interpreted as an indication of a pivotal role of ACAT-2 in atherosclerosis [43, 44] .
Acyl coenzyme A:cholesterol acyltransferase inhibition in clinical trials
Two ACAT inhibitors, CL 277081 and DuP-128, were studied for safety and efficacy in the 1990s. Although both compounds were well tolerated, their efficacy in improving lipid profiles was limited at the given doses [45] [46] [47] .
A new ACAT inhibitor, avasimibe, demonstrated superior effects on lipid levels compared with CL 277081 and DuP-128 in animal models. Avasimibe was investigated for safety and efficacy in 130 patients with combined hyperlipidemia and hypoalphalipoproteinemia. These patients were randomly allocated to placebo or one of four different doses of avasimibe once daily for 8 weeks. of plasma triglycerides (mean reduction 23%) and VLDL (mean reduction 30%), whereas no effects on total cholesterol, LDL-C, HDL-C, apoB, and apoA levels were shown. Avasimibe was well tolerated at all doses [48] . In another study, 27 patients with homozygous familial hypercholesterolemia were treated in a double-blind crossover design for 12 weeks with avasimibe with and without atorvastatin, and for 6 additional weeks with placebo. Avasimibe monotherapy did not result in significant changes in lipid profiles [49 & ]. The A-PLUS (Avasimibe and Progression of Lesions on UltraSound Avasimibe and Progression of Lesions on UltraSound) study was the first trial to directly assess the efficacy of avasimibe in decreasing the progression of atherosclerosis. In total, 639 patients with stenotic coronary arteries were randomized to either placebo or one of three doses of avasimibe for 24 months, and received statin therapy if LDL-C targets were not reached. Intravascular ultrasonography (IVUS) was used to measure coronary plaque volume, and changes in lipid profiles were recorded. Surprisingly, patients treated with avasimibe showed a nonsignificant tendency toward greater progression of absolute plaque volume and percentage atheroma volume (0.4, 0.7, 0.8, and 1.0%, for placebo and different doses of avasimibe, respectively). Moreover, avasimibe resulted in increased LDL-C levels (1.7 versus 7.8, 9.1, and 10.9%, respectively), which may be a result of pharmacokinetic interaction with the concomitantly taken statins and might explain the observed enhanced progression of plaque volume [50] . The avasimibe study program was discontinued upon these results.
Avasimibe resulted in dose-independent reductions
Pactimibe, a nonselective ACAT inhibitor, was evaluated for effects on atherosclerosis and change in lipid levels in the ACTIVATE (Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation) trial [51] . In total, 526 patients with coronary artery stenosis were randomized to 18 months of treatment with either pactimibe or placebo. Pactimibe failed to reduce progression of atherosclerosis, as represented by the change in percentage atheroma volume, compared to placebo. Moreover, pactimibe adversely influenced total atheroma volume and atheroma volume in the most diseased subsegment. Like avasimibe, pactimibe had no favorable effects on lipid levels. The study was not powered to detect clinically relevant outcome measures. The unfavorable results of pactimibe led the developer of pactimibe, Sankyo, to terminate the pactimibe program, thereby prematurely ending the CAPTIVATE (Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition Treatment Effects) trial. The CAPTI-VATE trial aimed to investigate the efficacy of pactimibe in reducing the progression of carotid atherosclerosis in patients with familial hypercholesterolemia [52 && ]. A total of 892 patients were randomized to either pactimibe or placebo, in addition to lipid-lowering therapy. Although CAPTIVATE intended to treat patients for 24 months, the study was terminated after 15 months. An analysis of 716 patients treated with pactimibe for at least 40 weeks showed pactimibe to be ineffective in reducing progression of carotid atherosclerosis as indicated by the maximum carotid intima-media thickness compared with placebo, whereas the mean thickness progressed in the pactimibe while not progressing in the placebo group. Moreover, significantly more major cardiovascular events were seen in the pactimibe group than in the placebo group.
The striking discrepancy between the efficacy of ACAT inhibitors in humans and most animal models might be explained by the large differences in ACAT expression and lipid metabolism between species [53] . Moreover, in animal experiments, ACAT inhibitors were tested under atherogenic circumstances that do not necessarily mimic the process of atherogenesis in humans.
Future perspectives
The negative results of studies with different ACAT inhibitors in humans highlight the difficulty to specifically target ACAT isoforms in certain cell types (i.e., macrophages and enterocytes). To the best of our knowledge, no ACAT inhibitors are tested in phase 1 and 2 trials at this moment, and it remains to be seen whether such programs will be initiated after the failing trials in the last decade.
CONCLUSION
The failures described in this review bolster the statement that data about the clinical relevance of a given biomarker for CVD outcome, derived in animal and epidemiological studies, should be interpreted with great caution once used for drug development. Interventions that specifically address these 'CVD risk biomarkers' do not necessarily result in the anticipated beneficial clinical outcome. Unfortunately, there are no free rides in preventive medicine; clinical outcome trials, either based on endpoints or validated surrogate markers (i.e., IVUS), will remain crucial to define best practice.
